Compare RAYA & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAYA | MDCX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 15.9M |
| IPO Year | 2021 | 2025 |
| Metric | RAYA | MDCX |
|---|---|---|
| Price | $2.37 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 35.8K | ★ 1.5M |
| Earning Date | 04-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.25 |
| 52 Week High | $10.14 | $3.05 |
| Indicator | RAYA | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 38.81 |
| Support Level | $2.05 | N/A |
| Resistance Level | $2.95 | $0.41 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 30.65 | 7.96 |
Erayak Power Solution Group Inc is engaged in the manufacturing, research and development (R&D), and wholesale and retail of power solution products. The group focuses on manufacturing new energy storage and inverter devices. Its product portfolio includes sine wave and off-grid inverters, inverters and gasoline generators, battery and smart chargers, and custom-designed products. The products are used principally in agricultural and industrial vehicles, recreational vehicles (RVs), electrical appliances, and outdoor living products. The company generates the majority of its revenue from Inverters. The company generates revenue from five main markets, which are China, Poland, Mexico, the U.K., and Portugal. It derives maximum revenue from China.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.